Sygnature Discovery
Based at the company’s headquarters, Dr. Daniel Weston has been named associate director to support Sygnature’s metabolism studies. He most recently worked at AstraZeneca.
He told us, “In my new role at Sygnature Discovery, I will be focusing on providing differentiated capabilities around metabolite characterisation to add scientific value at key decision points.”